Since it was founded in 1929, by Henri Beaufour, Ipsen has developed, and made available to patients, a number of products in Oncology, Neuroscience, Rare Diseases and Consumer Healthcare. Global footprint, acquisitions, partnerships, scientific collaborations and innovations: learn about the development of our group over the years.

2017  Paris (France), 9 January 2017 – Ipsen announced that it has entered into a definitive agreement to acquire global oncology assets from Merrimack Pharmaceuticals, including its key marketed product ONIVYDE® (irinotecan liposome injection) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy, in combination with fluorouracil and leucovorin. Under the terms of the agreement, Ipsen will gain exclusive commercialization rights for the current and potential future ONIVYDE indications in the U.S., as well as the current licensing agreements with Shire for commercialization rights ex-U.S. and PharmaEngine for Taiwan. The transaction also includes Merrimack’s commercial and manufacturing infrastructure, and generic doxorubicin HCl liposome injection. The transaction represents a unique opportunity and a strong strategic fit for Ipsen. ONIVYDE is a clinically differentiated and FDA-approved product for patients with high unmet medical needs. 2017

Exelixis, Inc. and Ipsen jointly announced an exclusive licensing agreement for the commercialization and further development of cabozantinib, Exelixis’ lead oncology drug. Under the agreement, Ipsen will have exclusive commercialization rights for current and potential future cabozantinib indications outside the United States, Canada and Japan, including COMETRIQ®, which is currently approved in the European Union (EU) for the treatment of adult patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). The companies have agreed to collaborate on the development of cabozantinib for current and potential future indications. Exelixis will maintain exclusive commercial rights for cabozantinib in the United States and Canada, and continue its discussions to partner commercial rights in Japan.


  • April 1st: Ipsen opened its new peptide-driven R&D center in Cambridge (USA).
  • May, 19: Ipsen strengthened its oncology expertise with the acquisition of OctreoPharm Sciences, a German company developing innovative radiopharmaceutical products for the diagnosis and treatment of neuroendocrine tumors.
  • July 18: The Food and Drug Administration approved botulinum toxin Dysport® as a treatment for adult upper-limb spasticity in the US.
  • August,3: Ipsen’s partner Lexicon Pharmaceuticals announced positive results from a late-stage trial that evaluated the efficacy and safety of telotristat etiprate for carcinoid syndrome patients with advanced neuroendocrine tumors whose symptoms are inadequately controlled by somatostatin analogs.
  • Ipsen strengthened its primary care portfolio with the launch in France of strawberry-flavored Smecta® and Smectalia® stick for adults, an OTC ready-to-use formulation of Smecta®.

  • Somatuline® Depot® (lanreotide) Injection 120 mg (referred to as Somatuline®) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Pancreatic and gastrointestinal neuroendocrine tumors are rare cancers. There are an estimated 112,000 individuals currently living with pancreatic and gastrointestinal neuroendocrine tumors in the U.S
  • Ipsen announces FDA acceptance of filing for Dysport® in the treatment of upper limb spasticity in adult patients
  • Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences. The 2011-2014 collaboration enabled significant steps forward in the understanding of basic biological mechanisms. Ipsen to support innovative Salk investigations into biology for another three years
  • The Fondation Ipsen celebrates its 30th anniversary with a prestigious conference on the perspectives of cancer research, “Biology viewed through the prism of cancer”, attended by 8 Nobel Prize laureates and the greatest scientists in biomedical research.

  • Teijin Pharma Limited and Ipsen launch of Somatuline® 60/90/120 mg for subcutaneous injection in Japan for the treatment of acromegaly and pituitary gigantism.
  • Ipsen and Inspirations Biopharmaceuticals announce closing of the sale of OBI-1 and Milford facility to Baxter International
  • Health Canada has granted amarketing authorization for Dysport® for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age. Medicis Aesthetics Canada, a division of Valeant Pharmaceuticals, will market Dysport® for use in aesthetic medicine in Canada.
  • Christel Bories joins Ipsen as Deputy CEO. Working alongside Marc de Garidel, Chairman and CEO, Christel Bories is responsible for accelerating the execution of the Group’s strategy.
  • Ipsen strengthens its neurology R&D capabilities with the acquisition of Syntaxin, a leader in recombinant botulinum toxin technology.
© Gerard Uferas IPSEN 30_01_12 SIGNE

Ipsen and Active Biotech present encouraging results from the tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer and initiate a new phase II, proof-of-concept clinical trial to evaluate the safety and efficacy of tasquinimod in other cancer indications.

Somatuline® receives marketing authorization in Japan for the treatment of acromegaly and pituitary gigantism and becomes Ipsen’s first drug available worldwide.

Inspiration Biopharmaceuticals, Inc., Ipsen’s partner, initiates a voluntary reorganization plan of its activities under the Chapter 11 of US Bankruptcy Code.


Ipsen announces a new growth strategy based on three pillars:

  • focus resources and investments on specialty care
  • invest to grow through the development of new compounds and product life-cycle management programs
  • leverage the full potential of the Group’s geographical footprint

Ipsen and the Salk Institute renew the “Ipsen Life Sciences Program” for a further three years.

Syntaxin and Ipsen enter into a strategic agreement to develop novel botulinum-toxin therapeutics.

Ipsen strengthens its business in urology-oncology with the acquisition of the rights to Heavy® (a drug aimed at improving bladder cancer detection) and the establishment of two significant partnerships with: Active Biotech for the co-development and commercialization of tasquinimod (a molecule for the treatment of metastatic and castration-resistant prostate cancers), and Institut Gustave Roussy in the area of medical oncology to leverage the combined expertise of their respective R&D teams.

© gerard Uferas Ipsen sige 17_12_10
  • Ipsen and Inspiration Biopharmaceuticals Inc. enter into a partnership to create a hemophilia franchise.
  • Ipsen increases its presence in oncology and endocrinology in South-East Asia through a commercialization agreement with Invida.
  • Ipsen grants Menarini exclusive license rights to Adenuric® (for the treatment of chronic hyperuricemia in gout) in 41 countries. Ipsen retains co-promotion rights in France.
  • Ipsen and Rhythm Pharmaceuticals, a biotechnology company developing peptide therapeutics for metabolic diseases, enter into a license agreement for Ipsen’s proprietary peptide therapeutics targeting obesity, metabolic diseases, and gastrointestinal disorders.
  • Ipsen grants Rhythm an exclusive worldwide license for research, development, and commercialization of its melanocortin and ghrelin programs originating from Ipsen’s research.
  •  Marc de Garidel is appointed Chairman and Chief Executive Officer
2009 Ipsen and Galderma receive collective green light for Azzalure® from 15 European countries’ Health Authorities for the granting of national marketing authorizations for the treatment of glabellar lines.

Azzalure® receives marketing authorization in the UK, France and Germany. The FDA approves Dysport™ for therapeutic and aesthetic use.

The European Medicines Agency (EMA) delivers marketing authorization for the 6-month formulation of Decapeptyl® in nine European countries. The product is launched in France

© Gerard Uferas IPSEN WREXHAM 20_02_12

Ipsen initiates a partnership with the Salk Institute for Biological Studies (San Diego, US) aimed at improving understanding of proliferative and degenerative diseases.

Ipsen reinforces its presence in the US with three acquisitions: Tercica Inc. in endocrinology, Apokyn® in neurology and Vernalis’ US commercial operations, and all assets related to OBI-1 from Octagen in hematology.


  • The Group enters into a partnership with Galderma, for the development, promotion and distribution of the Group’s botulinum toxin type A in aesthetic medicine indications.
  • Somatuline® Depot obtains marketing authorization in the United States for the treatment of acromegaly. Somatuline® Depot is the first product stemming from Ipsen’s R&D to be approved by the FDA.
    Ipsen’s shares are admitted to the SBF 120 index in France.

  • Ipsen enters into an agreement with Medicis (now Valeant) to market its botulinum toxin in aesthetic medicine indications in the US, Canada and Japan.
  • Ipsen and Tercica complete worldwide strategic collaboration agreement in Endocrinology. Ipsen grants Tercica exclusive rights to market Somatuline® Autogel® in the United States and in Canada.
  • Tercica grants Ipsen exclusive rights to market Increlex™, a leading product in the United States for the treatment of short stature associated with severe primary IGF-1 deficiency in all territories excluding the United States, Japan, Canada, Taiwan and certain countries of the Middle East and North Africa.
2005 Ipsen’s shares are listed on Euronext Paris. Ipsen enters into a licensing agreement with Radius through which Radius acquires the exclusive worldwide rights (excluding Japan) to develop, manufacture and distribute Ipsen’s osteoporosis proprietary molecule.  2005
Ipsen Business feature in Wrexham, North Wales on January 22, 2010.AFP/PHOTO/ANDREW YATES. The Group opens a botulinum toxin manufacturing facility in Wrexham (United Kingdom). 2004
2003 Ipsen and Teijin enter into an agreement to develop and market four Ipsen products, notably Somatuline® Autogel®, in Japan and a Teijin product for the treatment of gout in Europe.  2003
 2001-2002 Ipsen launches Somatuline®Autogel® in the UK, France followed by many other countries, strengthening Ipsen’s competitive position. To the Group’s knowledge, Somatuline® Autogel® is the first semi-solid formulation for injection without any excipient, since the active substance controls the sustained release. 2001-2002

Ipsen and Teijin enter into an agreement to develop and market four Ipsen products, notably Somatuline® Autogel®, in Japan and a Teijin product for the treatment of gout in Europe

 1996  Ipsen launches Forlax®, a product used for the treatment of constipation. 1996
1995 The Group launches Somatuline®, its sustained-release peptide for the treatment of acromegaly and neuroendocrine tumors in France.  1995
  • Ipsen acquires Speywood, the company that developed Dysport® for the treatment of movement disorders and various forms of muscular spasticity.
  • This acquisition strengthens the Group’s presence in the UK and Northern Europe.
    Ipsen establishes a sales platform for its biological product and opens an office in Russia.
1992 Ipsen begins its development in China, with the opening of a representative office in Tianjin. Copyright davidpeart.com
The Group creates La Fondation Ipsen under the aegis of the Fondation de France. Its mission is to foster interactions between leading scientists in the field of life sciences.
1980 Ipsen initiates a partnership with Debiopharm. This collaboration leads to the marketing of Decapeptyl® in 1986. This analogue of natural GnRH hormone (or gonadotropin) is indicated for the treatment of prostate cancer, endometriosis and infertility. Decapeptyl® has been a key driver of the Group’s international expansion.  1980
1970 The Group enters an expansion phase with the launch of Ginkor®, Tanakan® and Smecta®. The Group creates Laboratoires Ipsen (Institute of Synthetic Products from Natural Extraction). 1970
1969  The Group opens its first research facility in Les Ulis (France). © Gerard Uferas IPSEN LES ULYS 04_12_12
The Group launches Citrate de Betaïne®, a product used in the symptomatic treatment of dyspepsia.
1929 Dr. Henri Beaufour creates Laboratoires Beaufour in Dreux (France) to launch Romarène®, a product derived from rosemary for the treatment of digestive disorders.  1929
Last update 05/09/2018